ClinicalTrials.gg
Not yet recruitingNCT07672782Updated Nov 9, 2026

Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva

A Phase 2 interventional study of Tisotumab Vedotin in Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer and Squamous Cell Carcinoma Vulva, sponsored by GOG Foundation. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by GOG Foundation · Phase 2, Interventional, and Treatment

How we know

Updated Nov 9, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Vulvar Neoplasms with a site in United States — 19 open to participants now, 29 under way, none of them phase 3. Vulvar Neoplasms · United States.

Planned enrollment
49th of 80
28 · median 46
Started
2026
with 4 others
Phase 2
24 of 107
7 open now
Primary completion
2029-03
later than 24 of 28 live
Registered
105th of 107
by date

Among the 107 studies in Vulvar Neoplasms with a site in United States, this one is the 49th largest by planned enrollment of the 80 interventional ones that give a count, is one of 5 that started in 2026, is one of 24 in phase 2, reaches primary completion later than 24 of the 28 other live ones, and was the 105th registered.

Vulvar Neoplasms

236 studies on the registry are indexed under Vulvar Neoplasms; 69 are open to participants now.

Browse Vulvar Neoplasms studies →

Open to participants now

19 of the 107 studies in Vulvar Neoplasms with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Vulvar Neoplasms studies recruiting now, 39 (74%) set no upper age limit and 7 (13%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Vulvar Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, single arm, phase 2 study designed to evaluate the efficacy of tisotumab vedotin in participants with recurrent or metastatic squamous cell carcinoma of the vulva by estimating the objective response rate.

Patients will receive tisotumab vedotin every 3 weeks (21 days plus or minus 3 days). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.

03

Conditions studied

  • Vulvar Carcinoma
  • Recurrent or Metastatic Vulvar Cancer
  • Squamous Cell Carcinoma Vulva

Keywords

  • Metastatic
  • Recurrent
  • Squamous Cell Carcinoma
  • Vulva
  • Advanced
  • Vulvar Cancer
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years, or considered an adult by local regulations, at time of consent.
  • Must sign an form (ICF) indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study prior to any other study-related assessments or procedures.
  • Has recurrent or vulva cancer with squamous cell histology, and:

    1. Has not received more than 2 prior systemic therapy regimens for recurrent and/or metastatic vulva cancer. Chemotherapy administered in the or neoadjuvant setting, or in combination with radiation therapy, should not be counted as separate systemic therapy regimen.
    2. Is not a candidate for curative therapy, including but not limited to radiotherapy or exenterative surgery.
  • according to v1.1 as assessed by the investigator, defined as:

    1. A minimum of one non-nodal lesion ≥10 mm in the longest diameter from a nonirradiated area. If target lesion(s) are located within previously irradiated area only, the participant can be enrolled only if there has been demonstrated progression in the "in field" lesion and upon approval of the sponsor's medical monitor.

      OR

    2. Lymph node lesion ≥15 mm in the shortest diameter from a non-irradiated area.
  • Must demonstrate acceptable screening laboratory values:

    1. Calculated (MDRD formula): ≥50 mL/min/1.73m\^2
    2. (ALT): ≤3× (ULN) (if liver tumor/metastases are present, then ≤5×ULN is allowed)
    3. Aspartate aminotransferase (AST): ≤3×ULN (if liver tumor/metastases are present, then ≤5×ULN is allowed)
    4. : ≤1.5×ULN (except in participants diagnosed with Gilbert's syndrome, direct bilirubin ≤2×ULN)
    5. : ≥5.6 mmol/L (9.0 g/dL)
    6. (ANC): ≥1500/μL (1.5x10\^9/L)
    7. count: ≥100×10\^9/L
    8. For participants NOT on anti-coagulation therapy:

      1. (aPTT): ≤1.5×ULN
      2. International normalized ratio (INR): ≤1.2
    9. For participants on anti-coagulation therapy:

      1. aPTT: ≤1.5×ULN
      2. INR: ≤2.5
  • Has performance status of 0 or 1 within 28 days prior to registration.
  • Has a negative serum pregnancy test for participants of . Participants that are , permanently sterilized or previously subjected to bilateral oophorectomy, bilateral salpingectomy and/or hysterectomy can be considered as not having reproductive potential.
  • Participants of reproductive potential must agree to use adequate during and for 6 months after the last study treatment administration. Adequate contraception is defined as highly effective methods of contraception. Two highly effective methods of contraception must be used in countries where this is required.
  • Must agree not to breastfeed or donate ova, starting at the time of informed consent and continuing through 6 months after receiving the last dose of study drug administration.
  • Testing for or C is not required for this study, however, if required by local institutional standards, has negative serology for hepatitis B surface antigen (HBsAg)/HBV DNA, or antibody (HCVAb) or RNA. Active hepatitis C is defined by a known positive HCVAb result and known quantitative HCV RNA results greater than the lower limits of detection of the assay.
  • Must be willing and able to adhere to the prohibitions and restrictions specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Has primary melanoma, adenocarcinoma, sarcomatoid, or other histologies not mentioned in inclusion criterion 3
  • Has bleeding issues or risks:

    1. Known past or current coagulation defects leading to an increased risk of bleeding
    2. Diffuse alveolar hemorrhage from vasculitis
    3. Known bleeding diathesis
    4. Ongoing major bleeding (ie, participant requires a transfusion of >2 concentrates within 14 days of the first dose of study treatment)
    5. Trauma with increased risk of life-threatening bleeding
    6. History of severe head trauma or intracranial surgery within 8 weeks of study entry
  • Has cardiovascular issues or risks:

    1. Clinically significant cardiac disease, including unstable angina or acute myocardial infarction, 6 months prior to screening
    2. Any medical history of congestive heart failure (grade III or IV as classified by the )
    3. Any medical history of decreased cardiac of \<45%
    4. A marked baseline prolongation of /QTc interval (eg, repeated demonstration of a QTc interval >450 msec)
    5. A complete left bundle branch block (defined as a QRS interval ≥120 msec in left bundle branch block form) or an incomplete left bundle branch block
  • Central nervous system (CNS): any history of intracerebral arteriovenous malformation, cerebral aneurysm, or stroke ( >28 days prior to screening is allowed).
  • Ophthalmological: Active ocular surface disease or a history of cicatricial conjunctivitis or inflammatory conditions that predispose to cicatrizing conjunctivitis (eg, Wagner syndrome, atopic keratoconjunctivitis, disease affecting the eyes), ocular Stevens-Johnson syndrome or toxic epidermal necrolysis, mucus pemphigoid, and participants with penetrating ocular transplants are ineligible. Cataracts alone is not an exclusion criterion.
  • Other cancer: known past or current other than inclusion diagnosis. Exceptions are malignancies with a negligible risk of or death (e.g., 5-year OS ≥90%) such as non-invasive basal cell carcinoma, non-invasive superficial bladder cancer, and ductal carcinoma in situ.
  • if the following criteria are NOT met: definitive therapy (eg, surgery or stereotactic brain radiotherapy) has been completed >8 weeks before the first dose of study treatment; no evidence of clinical or radiologic progression of the brain metastases; participant has completed perioperative therapy or steroid taper. NOTE: Chronic steroid therapy is acceptable provided that the dose is stable for 28 days prior to study enrollment.
  • Surgery/procedures: major surgery within 4 weeks (28 days) or minor surgery within 7 days prior to the first study treatment administration. Participants must have recovered adequately from the toxicity or complications from the intervention prior to starting study treatment. Participants who have planned major surgery during the treatment period must be excluded from the study.
  • Peripheral neuropathy ≥grade 2.
  • Prior anti-cancer therapy:

    1. Any prior treatment with MMAE-derived drugs (e.g. Brentuximab vedotin, Polatuzumab vedotin, Tisotumab vedotin, Disitamab vedotin).
    2. Radiotherapy for palliative intent within 21 days prior to the first administration of study treatment. Participants must have recovered from all clinically significant radiation-related toxicities. At least 42 days must have elapsed from the last administration of chemo-radiotherapy to first study treatment.
    3. Small molecules, chemotherapy, immunotherapy, or monoclonal antibodies within 28 days prior to the first administration of study treatment.
    4. Currently participating in or has participated in a study of an agent or device and received active treatment within 28 days prior to the first dose of study treatment.
  • Other:

    1. Ongoing significant, uncontrolled medical condition.
    2. Clinically significant active viral, bacterial, or fungal infection requiring IV or oral treatment with antimicrobial therapy ending \<7 days prior to first study treatment administration.
    3. Clinically relevant bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage.
    4. Participants with clinical symptoms or signs of gastrointestinal obstruction and who require parenteral hydration or nutrition at the time of the first dose of study treatment.
  • Has known (HIV) infection that is not latent or well controlled on antiretroviral therapy; known medical history of or C infection. Note: No testing for HIV, hepatitis B, or is required, unless mandated by local health authorities.
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (dose exceeding 10 mg daily of prednisone or equivalent) or any other form of therapy within 7 days prior to the first dose of tisotumab vedotin.
  • Is pregnant or intends to conceive children within 6 months of ending study treatment.
  • Is breast feeding and cannot discontinue breast feeding for the duration of the study and ≥6 months after the last study treatment administration.
  • Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments.
  • Known allergies, , or intolerance to study treatment or its (refer to the Investigator's Brochure for further information on tisotumab vedotin).
  • Has known psychiatric or substance abuse disorders that would interfere with cooperating with the requirements of the study.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Tisotumab vedotin

    Tisotumab vedotin 2.0 mg/kg IV (maximum of 200 mg for patients ≥100 kg) every 3 weeks (21 days)

    Drug: Tisotumab Vedotin

Interventions

  • Tisotumab vedotin is an antibody-drug conjugate (ADC) directed against tissue factor (TF) and is composed of an IgG1 human monoclonal antibody chemically conjugated via a protease cleavable valine citrulline linker to the drug MMAE.

    Also known as: Tisotumab vedotin-tftv, Tivdak

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Complete or partial objective tumor response as measured by CT scan, PET-CT or MRI and assessed by RECIST v. 1.1 criteria

    Time frame: Measured from study enrollment to 6 months

Secondary outcomes

  1. Nature and Degree of Adverse Events (Safety and Toxicity)

    Nature and degree of adverse events as assessed using CTCAE v6 including frequencies and maximum grade by term and category

    Time frame: Measured from the time of the first dose of study treatment until 30 days after the last dose of study treatment.

  2. Progression Free Survival

    Progression-Free Survival (PFS) is defined as the duration of time from study enrollment to time of progression or death, whichever occurs first. Disease progression will be measured by CT scan, PET-CT or MRI and assessed per RECIST 1.1.

    Time frame: Measured from study enrollment then every 9 weeks for the first 36 weeks and then every 12 weeks thereafter until time of documented disease progression or death, whichever occurs first assessed up to 5 years or study closure.

  3. Overall Survival

    Overall survival (OS) is defined as the duration of time from the start of study treatment to time of death or the date of last contact.

    Time frame: Measured from study enrollment to time of death or the date of last contact assessed up to 5 years or study closure.

  4. Duration of Response

    Time of initial tumor response (among confirmed responses) to progression, death, or date last scanned (if censored).

    Time frame: Measured from study enrollment then every 9 weeks for the first 36 weeks and then every 12 weeks thereafter until time of documented disease progression or death, whichever occurs first assessed up to 5 years or study closure.

  5. Clinical Benefit Rate

    The proportion of patients with complete or partial responses, or those with stable disease among the sample of eligible and evaluable patients.

    Time frame: Measured from study enrollment then every 9 weeks for the first 36 weeks and then every 12 weeks thereafter until time of documented disease progression or death, whichever occurs first assessed up to 5 years or study closure.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Mar 2029, 28 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 29, 2026
StartEst.
Nov 2026
Primary completionEst.
Mar 2029
CompletionEst.
Dec 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedIfTesting for Hepatitis B or C is not required for this study, however, if required by local health authoritiesinstitutional standards, has negative serology for hepatitis B surface antigen (HBsAg)/HBV DNA, or hepatitis C antibody (HCVAb) or RNA. Active hepatitis C is defined by a known positive HCVAb result and known quantitative HCV RNA results greater than the lower limits of detection of the assay.
Exclusion criteria
  • EditedBrain metastases are allowed if the following criteria are NOT met: definitive therapy (eg, surgery or stereotactic brain radiotherapy) has been completed >8 weeks before the first dose of study treatment; no evidence of clinical or radiologic progression of the brain metastases; participant has completed perioperative corticosteroid therapy or steroid taper. NOTE: Chronic steroid therapy is acceptable provided that the dose is stable for 28 days prior to study enrollment.
  • EditedHas known seropositivity of human immunodeficiency virus (HIV) infection that is not latent or well controlled on antiretroviral therapy; known medical history of hepatitis B or C infection. Note: No testing for HIV, hepatitis B, or hepatitis C is required, unless mandated by local health authorities. Exceptions include latent or controlled HIV infection.
Nov 9, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameOverall Response RateMeasured from study enrollment then every 9 weeks for the first 36 weeks and then every 12 weeks thereafter through disease progression or completion of treatment assessed up to 5 years or study closure. → Measured from study enrollment to 6 months
Nov 9, 2026
Secondary outcomes
2 added
What changed in the outcomes
  • AddedDuration of ResponseTime frame: Measured from study enrollment then every 9 weeks for the first 36 weeks and then every 12 weeks thereafter until time of documented disease progression or death, whichever occurs first assessed up to 5 years or study closure.
  • AddedClinical Benefit RateTime frame: Measured from study enrollment then every 9 weeks for the first 36 weeks and then every 12 weeks thereafter until time of documented disease progression or death, whichever occurs first assessed up to 5 years or study closure.
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedIfTesting for Hepatitis B or C is not required for this study, however, if required by local health authoritiesinstitutional standards, has negative serology for hepatitis B surface antigen (HBsAg)/HBV DNA, or hepatitis C antibody (HCVAb) or RNA. Active hepatitis C is defined by a known positive HCVAb result and known quantitative HCV RNA results greater than the lower limits of detection of the assay.
    Exclusion criteria
    • EditedBrain metastases are allowed if the following criteria are NOT met: definitive therapy (eg, surgery or stereotactic brain radiotherapy) has been completed >8 weeks before the first dose of study treatment; no evidence of clinical or radiologic progression of the brain metastases; participant has completed perioperative corticosteroid therapy or steroid taper. NOTE: Chronic steroid therapy is acceptable provided that the dose is stable for 28 days prior to study enrollment.
    • EditedHas known seropositivity of human immunodeficiency virus (HIV) infection that is not latent or well controlled on antiretroviral therapy; known medical history of hepatitis B or C infection. Note: No testing for HIV, hepatitis B, or hepatitis C is required, unless mandated by local health authorities. Exceptions include latent or controlled HIV infection.
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameOverall Response RateMeasured from study enrollment then every 9 weeks for the first 36 weeks and then every 12 weeks thereafter through disease progression or completion of treatment assessed up to 5 years or study closure. → Measured from study enrollment to 6 months
    Secondary outcomes 2 added
    What changed in the outcomes
    • AddedDuration of ResponseTime frame: Measured from study enrollment then every 9 weeks for the first 36 weeks and then every 12 weeks thereafter until time of documented disease progression or death, whichever occurs first assessed up to 5 years or study closure.
    • AddedClinical Benefit RateTime frame: Measured from study enrollment then every 9 weeks for the first 36 weeks and then every 12 weeks thereafter until time of documented disease progression or death, whichever occurs first assessed up to 5 years or study closure.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07672782
Lead sponsor
GOG Foundation
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Nov 2026 (estimated)
Primary completion
Mar 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Sarin Chhab
Contact
schhab@gog.org
215-854-0770
Shanon Matkin
Contact
smatkin@gog.org
Yovanni Casablanca, MD
study chair · Atrium Levine Cancer - Carolinas Medical Center
Brian Slomovitz, MD
study chair · GOG Foundation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tisotumab vedotin

Start the discussion